Bone Cancer
155 clinical trials
1435 cell line models
7 approved drugs
Bone Cancer
Molecular Synopsis
Drugs and clinical candidates

7 drugs have received FDA approval for Bone Cancer:

  • 223
  • Denosumab
  • Doxorubicin Hydrochloride
  • Filgrastim
  • Pamidronate Disodium

52 drugs have a clinical trial registered for Bone Cancer.

1054 compounds have been tested in Bone Cancer (850 <= 500nM potency).

Sources:,, ChEMBL.

Clinical trials
There are 155 clinical trials for Bone Cancer, 78 of which have one or more drug interventions, 77 with no drug intervention.
Cell line models

There are 1435 Cell Line Models for Bone Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from mesh condition terms to Bone Cancer:
  • Bone Marrow Neoplasms
  • Bone Neoplasms
  • Giant Cell Tumor of Bone
The following terms have been mapped from to Bone Cancer:
  • Prostate cancer that is castration resistant (has not responded to treatments that lower testosterone levels). It is used in patients whose disease has metastasized (spread) to the bones and is causing symptoms but has not spread to other organs
  • Multiple myeloma that has metastasized to bone
  • Broken bones and other bone problems caused by multiple myeloma or by solid tumors that have metastasized (spread) to bone. This use is approved for the Xgeva brand of denosumab
  • Breast cancer that has metastasized (spread) to bone
  • Osteoporosis in men and postmenopausal women who have a high risk of breaking bones. This use is approved for the Prolia brand of denosumab